Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

• Main Authors: Donger Zhang (Author), Xia Li (Author), Jing Ding (Author), Xiatong Ke (Author), Wenpei Ding (Author), Yinan Ren (Author), He Xu (Author), Hongchao Li (Author), Aixia Ma (Author), Wenxi Tang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....